BMO Hosts Second Annual Obesity Summit on the Future of the GLP-1+ Market [Globe and Mail, The (Toronto, Canada)]
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
corbuspharma.com
Company Research
Source: Globe and Mail, The
NEW YORK, /CNW/ - Join BMO and industry leaders in New York on March 25 for the BMO 2025 Obesity Summit to discuss the growing $150 billion obesity therapies market. The Summit features an exciting line-up of leaders in the space as well as next generation players from Altimmune, Amgen, Corbus Pharmaceuticals and Eli Lilly, to FlyteHealth, Novo Nordisk, Roman Health, Scholar Rock and Structure Therapeutics. Participants will focus on the advances in GLP-1 drug therapies and feature expert insights from pharmacy benefit managers, patients, and providers to help identify and discuss the opportunities and challenges in this market. What: When: Where: Media: The BMO Obesity Summit will deliver thought leadership and corporate managem
Read more
Impact Snapshot
Event Time:
CRBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRBP alerts
High impacting Corbus Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CRBP
News
- Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of ObesityGlobeNewswire
- BMO Hosts Second Annual Obesity Summit on the Future of the GLP-1+ Market [Yahoo! Finance]Yahoo! Finance
- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $51.00 price target on the stock.MarketBeat
- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock, down previously from $75.00.MarketBeat
- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its price target lowered by analysts at Jefferies Financial Group Inc. from $70.00 to $53.00. They now have a "buy" rating on the stock.MarketBeat
CRBP
Earnings
- 3/11/25 - Beat
CRBP
Sec Filings
- 3/21/25 - Form 8-K
- 3/18/25 - Form 3
- 3/18/25 - Form 8-K
- CRBP's page on the SEC website